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Abstract
Introduction: Inflammatory breast cancer (IBC) is the most lethal form of breast cancers with a 5-year survival rate
of only 40 %. Despite its lethality, IBC remains poorly understood which has greatly limited its therapeutic management.
We thus decided to utilize an integrative functional genomic strategy to identify the Achilles’ heel of IBC cells.
Methods: We have pioneered the development of genetic tools as well as experimental and analytical strategies to
perform RNAi-based loss-of-function studies at a genome-wide level. Importantly, we and others have demonstrated
that these functional screens are able to identify essential functions linked to certain cancer phenotypes. Thus, we
decided to use this approach to identify IBC specific sensitivities.
Results: We identified and validated HDAC6 as a functionally necessary gene to maintain IBC cell viability, while being
non-essential for other breast cancer subtypes. Importantly, small molecule inhibitors for HDAC6 already exist and are in
clinical trials for other tumor types. We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor,
efficiently controls IBC cell proliferation both in vitro and in vivo. Critically, functional HDAC6 dependency is not
associated with genomic alterations at its locus and thus represents a non-oncogene addiction. Despite HDAC6 not
being overexpressed, we found that its activity is significantly higher in IBC compared to non-IBC cells, suggesting a
possible rationale supporting the observed dependency.
Conclusion: Our finding that IBC cells are sensitive to HDAC6 inhibition provides a foundation to rapidly develop novel,
efficient, and well-tolerated targeted therapy strategies for IBC patients.
Introduction
Inflammatory breast cancer (IBC) is the most lethal form
of breast cancer (representing approximately 5 % of all
breast cancers). Almost all women with primary IBC have
lymph node involvement, and at diagnosis approximately
25 % already have distant metastases. Critically, the 5-year
survival rate for this disease is only 40 %, compared to an
85 % survival rate in other breast cancer patients [1, 2].
Despite its lethality, IBC remains poorly understood and
systemic disease management relies mainly on chemother-
apy and standard anti-hormone or anti-human epidermal
growth factor receptor-2 (anti-HER2) therapy if the IBC
does express these receptors [3, 4].
Due to the unique biology, cancer cell homeostasis
presents different dependencies compared to non-
transformed cells. Importantly, interfering with these de-
pendencies has been successfully used as a highly select-
ive and low toxicity anticancer strategy [5, 6]. Although
efforts are underway to characterize IBC tumors at the
molecular level [3, 7, 8] no clinical application has yet
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emerged from these studies. We thus decided to utilize a
comprehensive and unbiased strategy to identify the
Achilles heel of IBC cells. We have pioneered the develop-
ment of genetic tools [9, 10] and experimental [11–13]
and analytical strategies [12, 14] to perform RNAi-based
loss-of-function studies at a genome-wide level. Import-
antly, we and others have demonstrated that these func-
tional screens are able to identify essential functions
linked to certain cancer phenotypes. Specifically in breast
cancer cells, these studies have revealed specific sensitiv-
ities associated with luminal and basal subtypes [12, 15]
and individual mutated bona fide cancer genes [16, 17].
Thus, we decided to use this approach to identify IBC-
specific sensitivities.
Through a genome-wide RNAi screen, we found and
validated that the viability of IBC cells depends on his-
tone deacetylase 6 (HDAC6) function. HDAC6 is a class
IIb histone deacetylase localizing mainly in the cytosol,
where it performs a diverse functional repertoire
through deacetylation of multiple targets [18–20]. Dur-
ing the last decade, HDAC6 has emerged as a master
regulator of the cellular protective response to cytotoxic
accumulation of toxic bioproducts [18–20]. Importantly,
there are small molecule inhibitors for HDAC6 currently
being tested in advanced clinical trials for other tumor
types (myeloma and lymphoid malignancies). Here,
using both in vitro assays and in vivo preclinical studies,
we demonstrated that Ricolinostat (ACY1215), a leading
HDAC6 inhibitor [21], attenuates progression of IBC.
These findings provide a direct rationale to developing
novel, efficient, and well-tolerated targeted therapies for
IBC patients.
Methods
Pooled shRNA screen experimental approach
We performed genome-wide pooled RNAi screens in 13
breast cancer cell lines (Additional file 1, for a table with
a complete list and characteristics of the cell lines used).
The library pool consists of 58,493 shRNAs integrated
into the backbone of miR-30 and cloned into the pGIPZ
lentiviral vector (Open Biosystems GIPZ Lentiviral
Human shRNA Library). These shRNAs target 18,661
human genes, which account for about 75 % of the hu-
man genome. Cell lines were transduced at a multiplicity
of infection (MOI) <0.3 in triplicate [12, 13]. After li-
brary transduction, cells that have incorporated the
GIPZ construct were selected based on the puromycin
selection expressed by the library constructs. The surviv-
ing cells were allowed to recover for 24 hours. These cells
were split into different aliquots containing 70 million
cells (approximately 1000 times representation of the
library). One aliquot was used for genomic DNA (gDNA)
extraction immediately after puromycin selection (t0) and
the other aliquote was passed in culture. Finally, gDNA
was extracted again after 10 doubling times (t10).
Next, we utilized NextGen-sequencing via the Illumina
HiSeq 2000 at 100 bp resolution to analyze shRNA
abundance at t0 and t10 time points [14, 22–24]. As a
first step, it is necessary to PCR out the shRNA library
integrated in the gDNA of each cell population. For this,
PCR-oligos that hybridize in a common region outside
the shRNA are used. After this PCR, we obtain a PCR
product that contains the shRNA library with the same
representation found in the cell population analyzed.
The hairpin sequence is extracted from the sequencing
read and compared to the reference sequence. Max-
imum alignment scores are identified as the primary
read; if multiple scores exist, the read is marked as am-
biguous and not utilized. It is estimated that 75 % of
short reads are verifiably read in genome-wide shRNA
screens utilizing next generation sequencing (NGS) for
deconvolution. An expanded shRNA screen method-
ology can be found in the supplementary material and
methods in Additional file 1).
Pooled shRNA screen analytical approach
Our ultimate goal was to identify genes that selectively
compromise IBC cell viability when silenced. This analysis
was divided onto several individual steps, as follows.
Individual shRNA analysis
ShRNA reads from T = 0 and T = 10 in all cell lines are
first normalized and converted to a log2 fold-change
score (log2FC), and then fitted to a Gaussian distribu-
tion. For each shRNA, individual t tests are performed
across screen triplicates. Bayesian linear modeling, a type
of moderated t test, is used to fit the data and accounts
for variance generated by the small sample size (n = 3)
typically utilized in shRNA screens [25]. This method
provided us with a fold-change and a statistical p value
for each shRNA in the library that represents the change
in abundance between T = 0 and T = 10 for each individ-
ual cell line.
Quality control of the screens
Once a p value is obtained for all shRNAs in all cell
lines, and in order to further determine the quality of
our screen data, we first looked for common essential
genes significantly depleted (> = 3 cell screened lines,
p <0.05, 2,555 genes). There is no gold standard set
of essential human genes to serve as a benchmark of
verifiable screen quality. However, housekeeping genes
and genes highly conserved across diverse species
have consistently been found to be commonly depleted
in shRNA screens, being enriched for essential functions
[15, 26]. We used Fisher’s exact test to evaluate the
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overlap between general essential genes identified by
our study and those previously reported [15].
RNAi-based classification of breast cancer cell lines
We determined whether essential genes emerging from
these screens could classify breast cancer cell lines. For
this, we identified shRNAs significantly depleted (p <0.05)
in over one third (n = 4) of screened breast cancer cell
lines. Then we selected the 30 % that varied most across
all of the lines (IQR of z scores over 70 % quartile) and
performed unsupervised hierarchical clustering using
Pearson correlation and complete linkage clustering.
Selective depletion in IBC cell lines (meta-analysis of shRNA
dropout screens)
Since we queried an overall comparison profile between
IBCs and non-IBCs, the subsequent p values generated
by c method [27] shown in the following formula:
Z ¼
Xk
i¼1ziffiffiffi
k
p ; zieN 0; 1ð Þ
such that each shRNA has two pooled IBC cell line z
scores to compare with pooled non-IBC cell line z
scores. In the above equation, zi is the z score indicating
the strength of evidence, for example, differential repre-
sentation score of a gene or a hairpin, in one source, say
number i from total number of k sources: zi follows a
standard normal distribution, so the integrated Z score
also follows a standard Gaussian distribution assuming
independence of all k evidences. The combined two-
tailed p value was calculated based on the integrated Z
score and utilized such that p <0.05 significance cutoff
corresponded to a minimum z comparative score of –
1.96, the negative z score indicating a direction of deple-
tion, positive indicating enrichment. As a further cutoff,
we selected shRNAs that had a log2FC of at least –1
(depleted by at least 0.5) in both IBC lines compared to
non-IBC cell lines.
Functional enrichment of IBC-depleted candidates
In order to see whether IBC-relevant classes of signifi-
cantly depleted shRNAs are related to functional cat-
egories characterizing IBC function and survival, we
compared the biological functions of the gene targets (as
assessed by gene ontology (GO) categories) of the
shRNAs identified from our screen. We used both the
Database for Annotation, Visualization, and Integrated
Discovery (DAVID) [28], which supports gene annota-
tion functional analysis using Fisher’s exact test and gene
set enrichment analysis (GSEA) [29], a K-S statistic-
based enrichment analysis method, which uses a ranking
system, as complementary approaches. For DAVID, the
71 gene candidates selectively depleted in IBC vs. non
IBC cell lines - representing the top best shRNAs -
comprised our input list. See also expanded material
and methods in Additional file 1.
HDAC6 regulon and HDAC6 score
We used a data-driven approach, utilizing the algorithm
for the reconstruction of gene regulatory networks
(ARACNe) [30] to reconstruct context-dependent sig-
naling interactomes (against approximately 2,500 signal-
ing proteins) from The Cancer Genome Atlas (TCGA)
RNA-Seq gene expression profiles of 840 breast cancer
(BRCA [31]), 353 lung adenocarcinoma (LUAD [32])
and 243 colorectal adenocarcinoma (COAD and READ
[33]) primary tumor samples, respectively. The parame-
ters of the algorithm were configured as follows: p value
threshold p = 1e − 7, data processing inequality (DPI) tol-
erance € = 0, and number of bootstraps (NB) = 100. We
used the adaptive partitioning algorithm for mutual in-
formation estimation. The HDAC6 sub-network was
then extracted and the first neighbors of HDAC6 were
considered as a regulon of HDAC6 in each context.
To calculate the HDAC6 score we applied the master
regulator inference algorithm to test whether HDAC6 is
a master regulator of IBC (n = 63) patients in contrast to
non-IBC (n = 132) samples. For the GSEA method in the
master regulator inference algorithm (MARINa), we ap-
plied the ‘maxmean’ statistic to score the enrichment of
the gene set and used sample permutation to build the
null distribution for statistical significance. To calculate
the HDAC6 score we applied the MARINa [34–36] to test
whether HDAC6 is a master regulator of IBC (n = 63) pa-
tients in contrast to non-IBC (n = 132) samples. The
HDAC6 activity score was calculated by summarizing the
gene expression of HDAC6 regulon using the maxmean
statistic [37, 38].
Only genes from the BRCA regulon were used when
the expression profile data came from HTP-sequencing
or Affymetrix array (Fig. 4a and d) but all genes in the
list from BRCA, COAD-READ and LUAD regulons were
considered when expression data were generated with
Agilent arrays (Fig. 4c) due to the low detection of >30 %
of the BRCA regulon genes in this platform.
Gene expression microarray data processing
The pre-processed microarray gene expression data
(GSE23720, Affymetrix Human Genome U133 Plus 2.0)
of 63 IBC and 134 non-IBC patient samples were down-
loaded from the Gene Expression Omnibus (GEO). We
further normalized the data by quantile algorithm and
performed non-specific filtering (removing probes with
no EntrezGene id, Affymetrix control probes, and non-
informative probes by IQR variance filtering with a cut-
off of 0.5), to 21,221 probe sets representing 12,624
genes in total. Based on QC, we removed two outlier
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non-IBC samples (T60 and 61) for post-differential ex-
pression analysis and master regulator analysis.
Cell culture
Cell lines
Non-IBC breast cancer cell lines were all obtained from
American Type Culture Collection (ATCC; Manassas,
VA 20110 USA). SUM149 and SUM190 were from
Asterand, and MDA-MB-IBC3 and Mary-X models were
obtained from Drs. Wendy Woodward and Mary
Alpaugh, respectively.
Western blots for HDAC6 knockdown
Puromycin-resistant, lentiviral shRNA constructs against
HDAC6 or scrambled shRNA (Thermo Scientific GIPZ;Wal-
tham, MA USA 02451) were co-transfected into Phoenix
cells along with helper packaging plasmids in order to pro-
duce viruses. The jETPEI transfection reagent and protocol
was used (Polyplus Transfection). Media were changed at
24 hours. Another 24 hours later, media were collected and
filtered through a 0.45-μ syringe unit (BD Falcon). The breast
cancer cells of interest were then transduced with the virus
and selected for puromycin resistance for 48 hours and
allowed to recover for another 48 hours. Protein was har-
vested to assess knockdown. HDAC6 antibody (rabbit poly-
clonal, Santa Cruz sc-11420) was used at 1:1000, for 2 hours
at room temperature, and β-actin antibody (mouse, mono-
clonal, BD Biosciences, 558624) was used at 1:5000.
Percentage of apoptotic cells
To measure apoptosis, we utilized the Annexin-V/7-AAD
assay BD Bioscience# 559763; San Jose, CA 95131-USA)
which detects both early and late events in apoptosis. Float-
ing and attached cells were stained following the kit guide-
lines to analyze apoptosis and were evaluated using an
LSRIIB-FACS analyzer. When used together, 7-AAD and
Annexin-V provides a simple staining assay to monitor
apoptosis by flow cytometry that allows one to differentiate
between 1) intact cells, 2) cells in early apoptosis, which only
stain positive for Annexin-V, and 3) cells in later apoptosis,
which only stain for 7-AAD.
Cell number
Puromycin-resistant cells transduced with virus express-
ing shRNAs (against HDAC6 or scrambled control) were
first drug selected and then left to recover for 24 hours.
Then these cells were plated in 96-well culture plates
and the relative number of viable cells was measured in
four replicates at different time points using the The
CellTiter-Glo® Luminescent Viability Assay (Promega).
The number of cells in each time point was normalized
to scrambled shRNA and to the number of cells attached
24 hours after plating.
Drug treatments
For initial testing of Ricolinostat (Acetylon Pharmaceuticals,
Inc. Boston, MA USA 02210) and Tubastatin A (Selleck
Chemicals; Houston, TX 77054 USA), SUM-149 cells were
chosen to test compound efficacy. For in vivo testing,
2-month-old nu/nu female mice were orthotopically
transplanted with 1–5 million cells in the right mammary
fat pad (n > =6 were used for each of the treatments). Im-
munocompromised animals were used to support engraft-
ment of cancer cell lines of human origin. Tumors were
monitored until they reached a volume of about 150–
200 mm3. At this point, mice were treated with the corre-
sponding inhibitor in dimethyl sulfoxide (DMSO) diluted
1:10 in 5 % dextrose and phosphate-buffered saline (PBS).
Mice were monitored for 24 hours for comparison of
Ricolinostat vs. Tubastatin A, and were given a second
dose 4 hours before sacrifice. Protein was harvested
from tumors for western blot analysis of accumulated α-
tubulin levels. All in vitro and in vivo doses were calcu-
lated from established doses in the current literature.
For complete treatment response to Ricolinostat, ani-
mal tumor cells were inoculated as described above and
the animal treated after tumors reached a volume of
about 100–200 mm3. Animals were treated with a daily
dose of Ricolinostat at 50 mg/kg for 5 days per week
during the entire follow up (see treatment schema in
Fig. 3c).
Statistical differences were evaluated with the one-
tailed t test (n > =6 per cohort). In the corresponding co-
horts Paclitaxel was dosed twice per week at 10 mg/kg.
All treatments (Ricolinostat, Tubastatin-A and Paclitaxel)
were administered intraperitoneally in a final volume of
100 μl.
Multivariate analysis
In order to evaluate whether the HDAC6 score has any
dependence on molecular subtype or clinical subgroups of
breast cancer, we fit a multiple regression model of HDAC6
score on IBC and PAM50-defined molecular subtypes (nor-
mal, luminal-A, luminal-B, basal, or HER2), IBC and
immunohistochemically (IHC)-defined estrogen receptor
(ER)–progesterone receptor (PR) status (ER–PR: positive
or negative) and IBC, PAM50 and ER–PR and then ap-
plied analysis of variance (ANOVA) to compare with the
single regression model using IBC only as the predictor.
Ethics, consent and permission
All animal experimentation has been authorized by the
IACUC committee at MSSM (Animal Protocol Reference
#IACUC-2014-0104). All genetics data analyzed in this
manuscript were publically available from The Cancer
Genome Atlas (TCGA) and the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)
databases.
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Results
Identification of HDAC6 as the Achilles heel of IBC cells
Loss-of-function screening using genetic tools [12, 39, 40]
represent a powerful strategy to interrogate gene
function at the genome-wide level. We [9, 12] and
others [40, 41] have developed RNAi-based genetic
approaches to perform high-throughput (HTP)
screens in mammalian systems. Using this technology,
we performed genome-wide pooled RNAi screens in
13 breast cancer cell lines (2 IBC and 11 non-IBC
lines, including 4 luminal, 4 basal-B, 3 basal-A) and 2
non-transformed mammary epithelial lines using a
lentiviral library of shRNA-miRs [9] containing approxi-
mately 58,000 different shRNAs targeting approximately
18,500 human genes (Fig. 1a). These models were selected
because they recapitulate the genetics and drug sensitivity
of the main molecular subtypes of human breast cancer
[42]. The screens were performed as we have previously
described [12, 13] (see also description in “Methods”).
The resulting dataset contained data points from 90
independent cell populations.
As a first step in our studies we performed QC studies
in our screens. Screens were highly reproducible
between biological replicates with correlation between
0.8 and 0.97 for all cell lines (Figure S1a in Additional
file 2). Next, we looked for essential genes across mul-
tiple cell lines. For this, housekeeping and highly con-
served genes are commonly found depleted in shRNA
screens, independent of cell type [12, 15, 40, 43]. We
thus used these genes as a first metric of screen qual-
ity. As previously reported, genes significantly depleted
(p <0.05 in > =3 screens, 2,555 genes) were signifi-
cantly enriched in housekeeping functions involving
the ribosome, proteasome, spliceosome, DNA replication,
protein metabolism and mRNA processing (Figure S1b in
Additional file 2). Notably, there was highly significant
overlap (p <7.2 × 10^−18; Fisher’s exact test) between gen-
eral essential genes identified by our study and those pre-
viously reported [15] (Figure S1c in Additional file 2).
Next, we determined whether essential genes emerging
from these screens could classify breast cancer cell lines
consistently with functional genomics studies, as we [12]
and others [15] have previously shown. As expected, un-
supervised hierarchical cluster analysis divided the cell
lines into two major groups enriched in luminal and
basal subtypes due to subtype-specific sensitivities
(Fig. 1b). Interestingly, the IBC cell lines appeared as an
independent sub-cluster within the basal-enriched clus-
ter subtype. This suggests that IBC cells present a highly
specific profile of essential genes that is not recapitulated
by other breast cancer subtypes.
Finally, to achieve an overall profile of IBC vs. non-
IBC dependencies, we selected shRNAs significantly and
globally depleted in IBC lines vs. non-IBC (p <0.05 and
log2FC or log2FC <-1). Additionally, to prevent selection
of genes that were essential in non-transformed cells we
required that selected shRNAs were not significantly de-
pleted (p <0.05 and log2FC <-1) in the two non-
transformed lines. This yielded 71 candidate genes
(Table S1 in Additional file 3). We show the top 20 as a
heatmap, in order of global IBC-specific depletion sig-
nificance (Fig. 1c).
Next, we investigated whether significantly depleted
shRNAs specific to IBC cells cluster within specific func-
tional categories. To create a thorough portrait of func-
tionally enriched IBC pathways, we used both DAVID
[28] and GSEA [29] as complementary approaches in
order to perform functional enrichment analysis. DAVID
analysis, using the 71 candidate genes selectively de-
pleted in IBC vs. non IBC cells, yielded a set of Gene
Ontology (GO) biological processes that were directly
and specifically related to one of the candidate genes in
the list (i.e., HDAC6) (Fig. 1d). Thus, HDAC6 was the
only one of the 71 candidate genes that consistently
emerged as part of the top 15 statistically enriched bio-
logical processes identified by DAVID. Interestingly,
GSEA analysis, including all screened shRNAs ranked by
their depletion in IBC vs. non-IBC cells, yielded bio-
logical processes that were also specifically related to
HDAC6 (Fig. 1d) and HDAC6 was part of 1/3 of the top
15 statistically enriched processes. Thus, both functional
enrichment analysis tools provided a comprehensive and
intriguing portrait of the role of HDAC6 in IBC survival.
Critically, to achieve maximum translational relevance,
we paid special attention to candidate targets for which
there were clinically relevant pharmacological inhibitors.
In this aspect, HDAC6 [18, 20, 44] was also especially
interesting, as it represents a druggable target with
highly selective inhibitors [21, 45] already available in
the clinics, including Ricolinostat [21], which is currently
being evaluated in multiple clinical trials (Myeloma
NCT01997840, NCT01323751 and NCT02189343 and
Lymphoma NCT02091063) as an anticancer drug. Taken
together, all of the above provide a strong rationale to se-
lect HDAC6 as a primary candidate to validate our screen
and further investigate its role in IBC cell survival.
Validation of HDAC6 as a hit in the shRNA screen
Our genome-wide lentiviral shRNA library contains two
shRNAs against HDAC6. Thus, in order to individually
validate HDAC6 as a screen candidate, we first tested
the silencing efficiency of these shRNAs. Lentiviral-
mediated individual transduction of both shRNAs in the
IBC cell line SUM149 strongly reduced the protein
expression of HDAC6 (Fig. 2a). Next, these two shRNAs
were used to individually silence the expression of
HDAC6 in a series of cell lines consisting of two non-
IBC cell lines (MDA-MB-231 and MDA-MB-436)
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Fig. 1 (See legend on next page.)
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Fig. 2 Validation of histone deacetylase 6 (HDAC6) as a positive screen hit. a The western blot shows the efficiency of two independent shRNAs
in silencing HDAC6 in different breast cancer cell lines. The numbers below the blots indicate the fraction of protein remained normalized to
β-Actin and to the amount detected in cells expressing scrambled shRNA. b Graphic representation of Annexin-V/7-AAD assay to measure the
induction of apoptosis when HDAC6 is silenced by the shRNAs shown in a. Late apoptosis and early apoptosis are combined. c Illustrative
example of the FACS data obtained from the Annexin-V/7-AAD assay. d Cell numbers after several doubling times in inflammatory breast cancer
(IBC) and non-IBC cell lines when HDAC6 was knocked down (shRNA#1). The data are normalized to the scrambled shRNA control
(See figure on previous page.)
Fig. 1 Genome-wide loss-of-function screen to identify inflammatory breast cancer (IBC)-specific sensitivities. a Graphic representation of the
screen strategy described in the text. b Unsupervised cluster analysis of shRNA screens functionally classifies breast cancer models based on their
molecular subtype. c Top 20 genes that specifically compromise the viability of IBC lines when silenced. Heatmap displays the average fold-change in
shRNA representation for IBC and non-IBC lines as well as the individual z score for each of the cell lines in the screen. d The most statistically
significant enriched Gene Ontology (GO) terms (left) and gene set enrichment analysis (GSEA) modules (right) in the 71 genes that specifically
compromise the viability of IBC lines when silenced. HTP high throughput, MOI, multiplicity of infection
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randomly selected from the cell line series used in the
shRNA screens and three IBC cell lines. The IBC cell
lines consisted of the two lines used in our screen
(SUM149 and SUM190) and a new and independent
line, MDA-MD-IBC-3 [46].
We utilized the Annexin V/7-AAD assay to study the
induction of apoptosis in each cell line via shRNA
knockdown in comparison with control cells transduced
with a scrambled shRNA. This assay is able to monitor
both early and late events in apoptosis by flow cy-
tometry. These studies revealed that although HDAC6
silencing efficiencies were comparable between IBC
and non-IBC models (Fig. 2a), significant apoptotic
response was only observed in the IBC lines with minor
effects in the non-IBC cells (Fig. 2b and c). As expected,
growth curve studies showed reduction of cell prolifera-
tion in the IBC cell lines expressing shRNAs targeting
HDAC6 compared to controls expressing a scrambled
shRNA (Fig. 2d).
Inhibition of HDAC6 compromises the growth of IBC cells
in vitro and in vivo
To translate our discovery to preclinical animal
models, we decided to evaluate the impact of two of
the most potent and specific HDAC6 inhibitors previ-
ously described, Tubastatin A [45] and Ricolinostat [21],
in the viability of IBC cells. HDAC6 is well known to be
responsible for the deacetylation of α-tubulin [44] and ac-
cumulation of Ac-α-tubulin is commonly used to evaluate
the efficacy of HDAC6 inhibition [18, 20, 21, 44, 45].
Thus, we first compared accumulation of Ac-α-tubulin
in SUM149 cells when equal doses of Tubastatin A and
Ricolinostat were used. Our results showed that Ricoli-
nostat is a more potent inhibitor of HDAC6 in vitro
(Figure S2a in Additional file 4) and in vivo (Figure S2b
in Additional file 4).
Next, we evaluated the anticancer activity of Ricolino-
stat in IBC and non-IBC breast cancer models. For these
studies we used three IBC and four non-IBC models
[42]. Dose titration curves in cell culture showed that
Ricolinostat inhibited the growth of IBC cells more effi-
ciently than non-IBC cells (Fig. 3a). As expected, select-
ive inhibition of cell growth in IBC lines was associated
with induction of apoptosis (Fig. 3b). Finally, we per-
formed in vivo preclinical efficacy studies. We used three
IBC and two of the non-IBC xenograft models (one
luminal and one basal) mentioned above. The IBC
cell models included both lines used in our screen
(SUM149 and SUM190) and a unique IBC human-
patient-derived xenograft (PDX) model (Mary-X) that
faithfully recapitulates the dermal lymphatic invasion
phenotype characteristic of human IBC [47, 48]. Animals
were dosed with 50 mg/kg/day of Ricolinostat, which was
previously shown to result in plasma exposure levels
consistent with those observed clinically [21]. As observed
in vitro, treatment with Ricolinostat in vivo significantly
reduced the growth of IBC models without affecting the
non-IBC cells (Fig. 3c). For comparison of the anticancer
response we performed parallel treatments with a com-
monly used chemotherapeutic drug (paclitaxel) (Fig. 3c).
Interestingly, in IBC xenograft models Ricolinostat re-
duced tumor growth at least as much as was observed
with paclitaxel treatment.
To further demonstrate that inhibition of HDAC6
compromised the growth of IBC cells we performed
cell culture growth studies where SUM149 and MDA-
MB-231 were treated with second generation HDAC6
inhibitors that are more selective for HDAC6 than
Ricolinostat for off-target inhibition of class-I HDACs.
These studies showed that despite efficient inhibition of
HDAC6 in both cells lines (as demonstrated by accu-
mulation of acetylated α-tubulin) all these selective
HDAC6 inhibitors efficiently reduced the growth of
SUM-149 but had a minimal impact on MDA-MB-231
viability (Fig. 3d).
HDAC6 is a master regulator of IBC cells
Next, we aimed to investigate the dependency of
HDAC6 in IBCs. We hypothesized that differential ex-
pression and/or activity of HDAC6 between IBC and
non-IBC cells could mediate IBC cell sensitivity to
HDAC6 inhibition. We studied a series of primary breast
cancers (63 IBC and 134 non-IBC) representing the lar-
gest IBC data series with matched expression and copy
number variant (CNV) data from untreated tumors [49].
The HDAC6 locus is located in the chromosome-X at
the p11.23 region. This region is rarely amplified in
breast cancer, and we found no differences in the mRNA
expression level of HDAC6 between IBC and non-IBC
samples (Fig. 4d and data not shown). Thus, differential
expression of HDAC6 cannot be linked to the different
response observed after HDAC6 inhibition in IBC and
non-IBC. However, protein activity can be affected by
factors such as post-translational modifications, which
do not change protein or mRNA levels. We [36, 50, 51]
and others [52] have developed methods to infer protein
activity in primary cancer samples by reconstructing
regulatory networks using mRNA expression profiles.
Thus, we used the gene expression profile signatures in
over 900 breast cancer samples available in the TCGA
BRCA dataset to reconstruct the genome-wide regula-
tory networks of breast cancer cells, using the ARACNe
[30, 36] algorithm. These methods identified a regulon
consisting of 162 transcripts as a set of transcriptional
targets whose expression is affected by HDAC6 activity
(Fig. 4a). GO term enrichment analysis (DAVID) con-
firmed that this list was enriched in genes involved
in canonical HDAC6 functions, such as response to
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Fig. 3 (See legend on next page.)
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Fig. 4 Histone deacetylase 6 (HDAC6) activity is higher in primary inflammatory breast cancer (IBC) than in non-IBC. a Identification of the regulon
controlled by HDAC6. The table shows the GO terms associated with the 162 transcripts of the HDAC6 regulon in breast cancer. b Venn diagrams
showing the overlap between the HDAC6 regulons obtained from the analysis of the breast cancer (BRCA), colorectal cancer (COAD-READ) and
lung adenocarcinoma (LUAD) data sets from The Cancer Genome Atlas (TCGA). c HDAC6 activity score inferred by expression of HDAC6 regulon
genes upon treatment with Ricolinostat for 0, 3, 6 and 12 hours (left). Expression change of the HDAC6 regulon network over time upon Ricolinostat
treatment at 0 and 12 hours (right): node is color-coded by z-score-transformed expression with red indicating high and blue low expression, and node
size is also proportional to the corresponding expression. Edge is coded by the Pearson correlation of HDAC6 and corresponding regulon node with
red indicating positive and blue negative, and the width is proportional to the absolute correlation value. d mRNA expression levels (left) and the
HDAC6-score (right) in primary IBC and non-IBC clinical samples. ARACNe reconstruction of gene regulatory networks
(See figure on previous page.)
Fig. 3 Small molecule inhibitors of histone deacetylase 6 (HDAC6) as anticancer strategy in inflammatory (IBC). a Normalized numbers of
cells when cultures are treated with different concentrations of Ricolinostat for two doubling times. b Induction of apoptosis as measured
by Annexin-V/7-AAD assay in cells shown in a. c Growth of IBC cells grown as xenograft models treated with Ricolinostat (50 mg/kg once
daily for five days a week). Treating with paclitaxel (10 mg/kg/ twice a week) was also included for comparison of the anticancer response. The treatment
regimen is graphically shown. Red arrows in each growth curve represent the initiation of the treatments. d Biochemical selectivity profiles of the second
generation HDAC6 inhibitors (left table), their efficacy to induce accumulation of Ac-α-tubulin when IBC and non-IBC cells were treated at
2.5 μM for 16 hours (left panel), and as the impact that treating those cells for one doubling time had on cell number. In all panels asterisks indicate
statistically significant differences (t test, p <0.05) for treatments based on HDAC6 inhibitors: n >=6 for both in vitro and in vivo treatments
Putcha et al. Breast Cancer Research  (2015) 17:149 Page 10 of 14
unfolded protein-induced stress [18–20] (Fig. 4a). Inter-
estingly, when we analyzed lung (TCGA LUAD)-specific
and colorectal cancer (TCGA COAD-READ)-specific
HDAC6 regulons, generated by ARACNe analysis of the
corresponding TCGA datasets, we obtained a list of 147
and 138 genes, respectively, for which thge overlap with
the breast cancer regulon was highly significant (Fig. 4b).
This suggests that the transcriptional footprint of the
HDAC6 regulon is highly conserved among epithelial
cancer cells. Finally we integrated the expression of all
transcripts in the HDAC6 regulon in a single score,
termed the HDAC6 score (see “Methods”).
To demonstrate that the HDAC6 score is an indicator
of the HDAC6 activity, SUM149 cells were treated for 3,
6 and 12 hours with 2.5 uM of Ricolinostat and the
HDAC6 score for treated samples was compared to con-
trols. This study revealed that inhibition of HDAC6 sig-
nificantly attenuated the HDAC6 score (Fig. 4c and
Figure S3a in Additional file 5).
Finally, we evaluated the HDAC6 score in our series of
63 IBC and 134 non-IBC primary specimens. Import-
antly, IBCs had a significantly higher HDAC6 score than
non-IBCs (Fig. 4d). To further study whether the
HDAC6 score was influenced by the different compos-
ition in molecular subtypes between IBCs and non-IBCs
[53] we evaluated the HDAC6 score after stratifying the
tumor series based on their hormone receptor (HR)
status and their intrinsic molecular subtype [54]. Our
results revealed that the HDAC6 score was signifi-
cantly higher in IBCs compared with non-IBC inde-
pendently of those molecular characteristics (Figure S3b
in Additional file 5). Furthermore, multivariate analysis
taking into account these molecular classifications
demonstrated that there is no significant difference be-
tween the multi-variable model, considering PAM50,
ER–PR or both, and the single model with IBC only.
These data show that inflammatory vs. non-inflammatory
is the main feature that impacts on the HDAC6 score (see
table in Additional file 1). Overall these data revealed cor-
relation between IBC disease and the HDAC6 score,
which suggests a rationale for IBC dependency on
HDAC6.
Discussion
Inflammatory breast cancer is the deadliest clinical
subtype of breast cancer and also one of the most
poorly characterized at the molecular level. Poor un-
derstanding of this malignancy has greatly limited its
therapeutic management. Our finding that IBC cells
are more sensitive than non-IBC cells to HDAC6 in-
hibition represents a novel opportunity to develop
therapeutic regimens specifically suited for IBC pa-
tients. The relevance of our data is enhanced by the
fact that small molecule inhibitors for HDAC6 are
already in clinical trials (https://clinicaltrials.gov/ct2/
results?term=acy-1215&Search=Search) and there are
already maximum tolerated dose, toxicity and phar-
macokinetic data from phase I studies. Consequently
the transition of our finding to clinical studies can be
greatly accelerated.
HDAC6 is a class-IIb histone deacetylase located mainly
in the cytosol, which displays diverse functions through
the deacetylation of multiple substrates [19, 55]. During
the last decade, HDAC6 has emerged as a master regula-
tor of the cellular protective response to accumulation of
protein aggregates and damaged mitochondria [18–20].
Misfolded polypeptides can be corrected by chaperones
[55]; however, when chaperone capacity is exceeded, they
form toxic intracellular protein aggregates that are then
eliminated by the proteasome and the aggresome-
autophagy pathway [19, 55]. HDAC6 was discovered to be
an essential component of the aggresome and HDAC6-
deficient cells fail to clear misfolded proteins [18–20]. This
generates endoplasmic reticulum (EnR) stress and triggers
an evolutionarily conserved response termed the unfolded
protein response (UPR). Initially the UPR activates pro-
survival mechanisms; however, if persistent, it leads to cell
death [56, 57]. Similarly, dysfunctional mitochondria ag-
gregate into aggresome-like structures also dependent on
HDAC6, called the mito-aggresome [55, 58]. Accumu-
lation of defective mitochondria also generates toxicity
that compromises cell viability [59, 60].
Why are IBC cells more dependent on HDAC6 func-
tion? Based on the current knowledge of HDAC6 func-
tion, some hypotheses appear especially reasonable
(Fig. 5). It is possible that IBC cells rely on the
aggresome-lysosome to clear toxic aggregates (protein,
mitochondria or both) more than non-IBC cells. De-
pendency on HDAC6 function may be associated with
higher steady-state levels of misfolded proteins and/or
damaged mitochondria and saturation of alternative de-
tox pathways such as proteasome-mediated proteolysis.
Thus, in those cases blockage of HDAC6 will impact
IBC homeostasis more severely. Alternatively, the differ-
ential response to HDAC6 inhibition could be deter-
mined by the stress levels already present in the cells
potentially even mediated by an altered microenviron-
ment in this disease. Homeostatic decisions in a cell,
such as life or death, are the result of multiple stimuli
[61, 62], and thus IBC sensitivity to HDAC6 inhibition
may be determined by non-HDAC6 specific stressors
already operational in the cell. Apoptotic thresholds or
baseline levels of pro-apoptotic proteins may already be
higher in IBC cells and may need relatively little further
accumulation, such as EnR stress caused by HDAC6 in-
hibition, to commit themselves to apoptosis [20, 63, 64].
However, if the last was true and IBC cells were primed
for apoptosis they should demonstrate sensitivity for any
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type of additional stress. But this is not the case and we
did not observe increased cell death in IBC cells com-
pared to non-IBC when these were treated with pacli-
taxel (Figure S4 in Additional file 6).
Finally, we should not dismiss the importance that
other HDAC6 substrates may have in the sensitivity
of IBC cells to HDAC6 inhibition. For instance, the
chaperone HSP90 is well-known to be a substrate of
HDAC6 and consequently HDAC6 inhibition leads to
hyperacetylation of HSP90 and loss of its function [65].
Remarkably, loss of HSP90 function impairs the stability
of genes involved in tumorigenesis and tumor mainten-
ance such as HIF-1 alpha [66], the breast cancer metas-
tasis suppressor 1, BRMS1 [67] or c-Raf and AKT [68].
Some limitations of our study need to be discussed. In
contrast to non-IBC cell lines, where multiple models
are available representing the major molecular subtypes
and origin source (primary vs. metastatic site), far fewer
IBC models have been described in the literature [69].
We were unable to obtain all of these models and conse-
quently we could only include the four that are available
in our study. Although the reduced number of IBC lines
can influence the functional studies presented here,
there are some facts that support a general impact of
HDAC6 function on IBCs. First, half of the IBC models
that were used in our studies represent the luminal sub-
type and the other half represent the basal subtype. As
HDAC6 inhibition compromised the growth of all these
IBC models a potential subtype bias is reduced. Second,
the strong association between the HDAC6 score and
IBC disease was found on analyzing primary tumors,
which argues against a potential bias between primary
and metastatic cells.
Conclusions
Overall, our data represent novel preclinical studies val-
idating HDAC6 inhibition as an anticancer strategy for
IBC patients. Two additional considerations for translat-
ing our finding to the clinical setting are worth mention-
ing. The first is the potential combination of HDAC6
inhibition with other therapeutic strategies. Multimodal
therapy is the standard approach for the vast majority of
solid tumors including breast cancers regimens based on
targeted therapies [70]. Remarkably, synergistic activity
between HDAC6 and proteasome inhibitors [21], and
HDAC6 inhibition and taxanes [71] has been described.
The second is the potential use of the HDAC6 score to
identify individual tumors that may be sensitive to this
new modality of targeted therapy. Preselection of pa-
tients for HDAC6 therapy using the HDAC6 score as a
predictive biomarker may be applicable not only to IBCs
but also to non-IBCs and other tumors. Future studies
should further investigate the mechanistic basis of the
sensitivity of IBC cells to HDAC6 inhibition and the pre-
dictive potential of the HDAC6 score in order to effi-
ciently apply targeted HDAC6 therapy in IBC.
Additional files
Additional file 1: Supplementary material and methods. Includes
more detailed information about the methodology of the shRNA screens
and the supplementary Tables 2 and 3. (DOCX 815 kb)
Additional file 2: Figure S1. Quality control studies of the shRNA
screens. a Representative image showing the Pearson and Spearman
correlation among the triplicates for T = 10 in the SUM149 cell line. b
GO-term and KEGG-pathway analyses using genes commonly depleted in
several cell lines (p <0.05 in >=3 cell lines, 2,555 genes) show enrichment
of genes related to essential functions. c Essential genes depleted in our
shRNA screen cell lines overlapped significantly with compiled screens
across 72 cell lines and subtypes of cancer (Fisher’s exact test). (EPS 3172 kb)
Additional file 3: Table S1. List of 71 candidate genes significantly and
globally depleted in inflammatory breast cancer (IBC) lines vs. non-IBC
(p <0.05 and log2 fold-change or log2FC <-1). (XLS 98 kb)
Additional file 4: Figure S2. Inhibition of HDAC6 activity by small
molecules in vitro and in vivo. The western blots show the accumulation
of Ac-α-tubulin when SUM149 cells were treated with Ricolinostat and
Tubastatin-A in vitro (a) and in vivo (b). (EPS 783 kb)
Additional file 5: Figure S3. Changes in the HDAC6 regulon network
upon Ricolinostat treatment and HDAC6 score in primary breast cancers.
a Alternative view of expression change of HDAC6 regulon network over
Fig. 5 Illustration of the hypotheses described in the text for the
dependency of inflammatory breast cancer cells on histone
deacetylase (HDAC6) function
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time upon Ricolinostat treatment at 0 and 12 hours as shown in Fig. 4c.
b The dot-plots show the HDAC6 scores in the inflammatory breast
cancer (IBC) and non-IBC primary tumor series when these samples were
stratified based on their HR status (left) and their PAM-50 molecular
subtype (right). (EPS 8784 kb)
Additional file 6: Figure S4. Response to paclitaxel treatment in breast
cancer cell line models. The bars indicates the normalized survival after
different breast cancer cell lines (inflammatory breast cancer (IBC) and
non-IBC) were treated for two doubling times with 10 uM of paclitaxel.
Expression change of HDAC6 regulon network over time upon Ricolinostat
treatment. (EPS 713 kb)
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